Jee Hye Kang PhD Candidate, Zappasodi Lab Biography Jee Hye Kang earned a Bachelor of Science in chemical biology from the University of California, Berkeley in 2018. Her research journey began in the laboratory of Dr. Jeffrey Bluestone at UCSF, where she studied immune-related adverse events associated with immune checkpoint inhibitor therapies. She is currently pursuing a doctorate in the Immunology & Microbial Pathogenesis program at Weill Cornell Medicine. Her research focuses on understanding how regulatory T cells are reprogrammed during immune checkpoint inhibitor therapy to enhance the effectiveness of cancer immunotherapy. By studying the molecular mechanisms underlying Treg dynamics, she aims to develop strategies that could improve clinical outcomes for cancer patients.